Global Anemia in Chronic Kidney Disease Market and Forecast Analysis 2018-2035: The Launch of Novel HIF Inhibitor Roxadustat will Offset Biosimilar Erosion of Epogen to Drive Market Growth

Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.

Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.

Market Snapshot

Key Topics Covered:

Forecast: Anemia In Chronic Kidney Disease

Treatment: Anemia In Chronic Kidney Disease

Epidemiology: Anemia In Chronic Kidney Disease

Marketed Drugs: Anemia In Chronic Kidney Disease

Pipeline: Anemia In Chronic Kidney Disease

For more information about this report visit https://www.researchandmarkets.com/research/tphdjk/global_anemia_in?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716